Diagnostic marker for coronary artery disease
A technology of coronary artery disease and index, applied in the field of diagnosis of coronary artery disease
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
example 1
[0077] Diagnosis of coronary artery disease using phosphatidylinositol (36:5) in peripheral blood as a molecular marker
[0078] To investigate the performance of phosphatidylinositol (36:5) as a novel marker of coronary artery disease, phosphatidylinositol (36:5 )concentration.
[0079] The subjects were patients with coronary artery disease, and plasma samples derived from patients provided by Proteogenex were used. The control group was adults without coronary artery disease. Experiments were performed using human tissues and genes of Shionogi & Company (Shionogi Company) after obtaining approval from the Ethical Research Review Board. Blood was collected with written consent and frozen in aliquots at -80°C.
[0080] The concentration of phosphatidylinositol (36:5) in the peripheral blood of the subject was quantitatively determined by liquid chromatography tandem mass spectrometry (hereinafter LC / MS / MS).
[0081] The specific LC / MS / MS system used by the inventors to de...
example 2
[0086] Figure 4 The results of the ROC analysis summarizing the results obtained in Example 1. The area under the curve (AUC) was 0.963.
[0087] according to Figure 4 The results showed that when the relative value of phosphatidylinositol (36:5) concentration was used to diagnose coronary artery disease, the cutoff value was 43%, and the concentration at or below the cutoff value could be diagnosed as probable coronary artery disease.
example 3
[0089] Diagnosis of coronary artery disease using lysophosphatidylinositol (20:5) in peripheral blood as a molecular marker
[0090] In order to investigate the performance of lysophosphatidylinositol (20:5) as a novel marker for coronary artery disease, the plasma of 20 people in the control group and 20 people in the coronary artery disease group were compared by the same method as Example 1. Lysophosphatidylinositol (20:5) concentration.
[0091] Figure 5 The relative values of the amount of lysophosphatidylinositol (20:5) in the plasma of the control group and the coronary artery disease group are summarized. The relative value of lysophosphatidylinositol (20:5) in the plasma of the control group was 100.
[0092] Lysophosphatidylinositol (20:5) concentrations were approximately 69% lower in the coronary artery disease group than in the control group, and a significant difference was observed (P<0.0001).
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


